ArticleFrontiers in oncology2025
Photodynamic therapy and tumor-treating fields therapy for newly diagnosed glioblastoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Photodynamic therapy for glioblastoma: a narrative review.Journal of neuro-oncology · 2025Review
- Relation between tumor treating fields usage rate ≥75% for the first 3 months and progression-free survival in patients with newly diagnosed WHO grade 4 gliomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and purpose: Various treatment methods, including photodynamic therapy (PDT), are used for glioblastoma (GBM), which is an intractable tumor. Our therapeutic strategy for glioblastoma has been based on resection (if possible), and PDT. On the other hand, after tumor-treating fields therapy (TTF) became available, we have actively recommended it to our patients who are eligible for it. In this report, we describe the clinical characteristics and disease course of glioblastoma patients treated by PDT + TTF at our hospital. Methods: A total of 14 patients with newly diagnosed glioblastoma, who underwent PDT + TTF from the time of insurance coverage of TTF were analyzed. The median age of the patients was 48 years. There were 10 men and 4 women, with a high prevalence of younger men. Results: The average duration of TTF was 8.9 (1-19) months, and the main reasons for its discontinuation were recurrence of the tumor and scalp problems. The median progression-free survival of the 14 patients who underwent PDT + TTF was 13.4 months, which tended to be longer than that of the 30 patients who underwent PDT without TTF (11 months). Of the 10 patients who relapsed, 2 had local recurrence and 8 had distant or disseminated recurrence. Two patients with local recurrence underwent repeat resection together with PDT. To date, the prognosis for patient survival of PDT + TTF appears favorable, with 6 patients surviving for more than 2 years. Conclusion: PDT + TTF treatment for newly diagnosed glioblastoma can be performed without any major adverse events, although there are some problems with the continuation of TTF, such as scalp problems and its high cost. More patients who underwent PDT + TTF relapsed with distant and/or disseminated recurrence than local recurrence, suggesting that this treatment strategy targets local recurrence. Our results demonstrate that combination therapy for newly diagnosed glioblastoma with PDT + TTF may prolong the time to recurrence and improve survival outcomes of patients, although the data in this study are preliminary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.